Compound 46 was deprioritized due to lower free drug fraction in the brain. To enable selection of a PK/PD candidate, high dose oral PK studies were carried out at 10 and 100 mg/kg for both compounds. Compound 37 demonstrated good dose linearity in brain, while 42 showed sub dose proportionality at 100 mg/kg (Figure ).